BGBIO.OL Live signals | Maximize Profits with Getagraph.com

SELL 5364 min ago

@ Kr.13.17

Issued: 30 May 2024 @ 09:40

Return: 7.58%

Previous signal: May 30 - 09:02

Previous signal: Buy

Return: 1.32 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 10:29):
Our systems believe the stock currently is overvalued by 6.06% compare to its pairs and should correct downwards.

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases...

Stats
Today's Volume	944 591
Average Volume	436 158
Market Cap	553.86M
EPS	Kr.0 ( 2024-05-23 )
Next earnings date	( Kr.-1.300 ) 2024-08-21
Last Dividend	Kr.0 ( N/A )
Next Dividend	Kr.0 ( N/A )
P/E	0.210
ATR14	Kr.0.690 (4.87%)

Correlation (AI algo v.1.1b): Overvalued: -6.06% Kr.13.31 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.92 (very strong)

Short: 0.00 (neutral)

Signal:(86) Neutral

BerGenBio ASA Correlation

10 Most Positive Correlations
IOX.OL	0.946
PLT.OL	0.928
ACC.OL	0.91
ARGEO.OL	0.9
ECIT.OL	0.898
VOW.OL	0.897
PCIB.OL	0.894
MEDI.OL	0.891
AZT.OL	0.884
HBC.OL	0.879

10 Most Negative Correlations
KOG.OL	-0.961
GOGL.OL	-0.935
REACH.OL	-0.923
ODL.OL	-0.912
VOLUE.OL	-0.901
AKBM.OL	-0.891
AGLX.OL	-0.879
MULTI.OL	-0.876
ELO.OL	-0.875
2020.OL	-0.871

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BerGenBio ASA Correlation - Currency/Commodity

0.46
( neutral )

0.38
( neutral )

-0.47
( neutral )

0.41
( neutral )

-0.13
( neutral )

BerGenBio ASA Financials

Annual	2023
Revenue:	Kr.354 000
Gross Profit:	Kr.-83.92M (-23 707.34 %)
EPS:	Kr.-0.130

FY	2023
Revenue:	Kr.354 000
Gross Profit:	Kr.-83.92M (-23 707.34 %)
EPS:	Kr.-0.130

FY	2022
Revenue:	Kr.389 000
Gross Profit:	Kr.389 000 (100.00 %)
EPS:	Kr.-0.390

FY	2021
Revenue:	Kr.774 000
Gross Profit:	Kr.0.00 (0.00 %)
EPS:	Kr.-3.52

Financial Reports:

No articles found.

BerGenBio ASA Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.